Publication Date:
2019
Short description:
Predictive and prognostic factors in HCC patients treated with sorafenib / Brunetti, O.; Gnoni, A.; Licchetta, A.; Longo, V.; Calabrese, A.; Argentiero, A.; Delcuratolo, S.; Solimando, A. G.; Casadei Gardini, A.; Silvestris, N.. - In: MEDICINA. - ISSN 1010-660X. - 55:10(2019), p. 707. [10.3390/medicina55100707]
abstract:
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed similar results in terms of survival in a non-inferiority randomized trial study considering the same subset of patients. Unlike other targeted therapies, predictive and prognostic markers in HCC patients treated with sorafenib are lacking. Their identification could help clinicians in the daily management of these patients, mostly in light of the new therapeutic options available in the first.
Iris type:
1.1 Articolo in rivista
Keywords:
Hepatocellular carcinoma; Predictive factors; Prognostic factors; Sorafenib; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinolines; Sorafenib
List of contributors:
Brunetti, O.; Gnoni, A.; Licchetta, A.; Longo, V.; Calabrese, A.; Argentiero, A.; Delcuratolo, S.; Solimando, A. G.; Casadei Gardini, A.; Silvestris, N.
Published in: